"Pentoxifylline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production.
| Descriptor ID |
D010431
|
| MeSH Number(s) |
D03.633.100.759.758.824.651.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pentoxifylline".
Below are MeSH descriptors whose meaning is more specific than "Pentoxifylline".
This graph shows the total number of publications written about "Pentoxifylline" by people in this website by year, and whether "Pentoxifylline" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pentoxifylline" by people in Profiles.
-
Phosphodiesterase inhibition promotes the transition from compensated hypertrophy to cardiac dilatation in rats. Pflugers Arch. 2006 Jan; 451(4):526-33.
-
Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats. Eur J Pharmacol. 2005 May 09; 514(2-3):201-8.
-
C-reactive protein predicts response to pentoxifylline in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2004 Oct; 6(6):731-4.
-
A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension. S Afr Med J. 2004 Oct; 94(10):833-4.
-
Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004 Feb 17; 109(6):750-5.
-
Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 2002 Nov 15; 90(10):1118-22.
-
The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002 Jun; 4(3):305-9.
-
Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001 Feb 27; 103(8):1083-8.
-
Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart. 2000 Oct; 84(4):438-9.
-
Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 1998 Apr 11; 351(9109):1091-3.